Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab + mFOLFIRINOX in CLDN18.2+ Metastatic Pancreatic Adenocarcinoma
NCT06396091Phase 1Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zolbetuximab in pancreatic adenocarcinoma (PDAC), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Safety assessed by Adverse Events at 16 months and 4 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06396091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396091.